Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Jason Westin, Julio Chavez, Stephen J. Schuster, Vladan Vucinic, Patricia A. Young, Patrick Connor Johnson, Stefania Bramanti, Alessandro Rambaldi, Javier Briones Meijide, Koji Kato, Juan-Manuel Sancho, Mi Kwon, Carlos Solano, Shaun Fleming, Saurabh Dahiya, Alejandro Martin Garcia-Sancho, Pedro Marques Ramos, David Pearson, Salif Diallo, Aiesha Zia, Eduardo Segura, Aisha Masood, Pere Barba
Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Abramson Cancer Center, University of Pennsylvania, University Hospital Leipzig, University of California, Los Angeles, Harvard University, Massachusetts General Hospital, IRCCS Humanitas Research Hospital, University of Milan, Ospedale Papa Giovanni XXIII, Hospital de Sant Pau, Kyushu University, Kyushu University Hospital, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital Clínico Universitario de Valencia, The Alfred Hospital, Monash University, Stanford Medicine, Stanford University, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Novartis (Switzerland), Novartis Institutes for BioMedical Research, Vall d'Hebron Hospital Universitari
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006946